HLS Therapeutics Inc Share Price Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded| Market Cap | 9.25Cr 8.08Cr 7.43Cr 6.93Cr 13Cr 880.54Cr 13Cr 89Cr 35Cr 432.83Cr 35Cr 34Cr 1.49TCr | P/E 2026 * |
-14.8x | P/E 2027 * | -98.6x |
|---|---|---|---|---|---|
| Enterprise Value | 9.25Cr 8.08Cr 7.43Cr 6.93Cr 13Cr 880.54Cr 13Cr 89Cr 35Cr 432.83Cr 35Cr 34Cr 1.49TCr | EV / Sales 2026 * |
1.59x | EV / Sales 2027 * | 1.44x |
| Free-Float |
99.47% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 01/05/2023 |
John Hanna
DFI | Director of Finance/CFO | 61 | 26/01/2024 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/06/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 12/03/2018 |
John Welborn
CHM | Chairman | 48 | 22/06/2023 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 9.25Cr | |
| +2.37% | +2.98% | +9.31% | +86.86% | 9.21TCr | |
| +0.51% | +0.43% | +44.87% | +152.61% | 5.6TCr | |
| +2.20% | +0.72% | -7.00% | +238.18% | 2.23TCr | |
| +1.26% | +5.43% | -9.79% | -27.12% | 799.99Cr | |
| +1.90% | +13.78% | -25.55% | -30.74% | 776.4Cr | |
| +1.89% | +6.02% | -9.81% | -28.92% | 666.05Cr | |
| -2.66% | +2.67% | +23.06% | +32.27% | 635.29Cr | |
| +0.17% | +0.88% | -2.15% | +21.78% | 535.83Cr | |
| +1.86% | +6.93% | -4.08% | -12.79% | 362.91Cr | |
| Average | +0.95% | +2.75% | +2.10% | +48.01% | 2.31TCr | |
| Weighted average by Cap. | +1.56% | +2.45% | +14.38% | +103.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.8Cr 5.07Cr 4.66Cr 4.35Cr 8.24Cr 552.52Cr 8.37Cr 56Cr 22Cr 271.59Cr 22Cr 21Cr 935.89Cr | 6.43Cr 5.62Cr 5.17Cr 4.82Cr 9.13Cr 612.35Cr 9.27Cr 62Cr 24Cr 301Cr 24Cr 24Cr 1.04TCr |
| Net income | -62.64L -54.76L -50.33L -46.91L -88.98L -60Cr -90.33L -6.04Cr -2.35Cr -29Cr -2.35Cr -2.3Cr -101.03Cr | -10.5L -9L -8L -8L -14.91L -10Cr -15.14L -1.01Cr -39.37L -4.91Cr -39.41L -38.57L -17Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
